Interventions
toxicity
TEM
BCc1 and Hep-S nanomedicines were designed by Sodour Ahrar Shargh Company based on nanochelating technology [TEM image of Hep-sHep-S toxicity was evaluated based on the guidelines of the Organization for Economic Co-operation and Development (OECD, guideline 420) regulations and by the LD50 evaluation test; these tests were conducted in the School of Pharmacy at Tehran University of Medical Sciences. The toxicity report of Hep-S shows that i.p LD50 of this structure is 54 mg/kg. Active pharmaceutical ingredient (API) synthesis of BCc1 and Hep-S nanomedicines was carried out by using the nanochelating technology in the laboratory of Sodour Ahrar Shargh Company.The two nanomedicines of BCc1 and Hep-S were used at the same time in the form of syrup as a two-medicine package to evaluate its effectiveness in comparison with a placebo. Two types of placebo syrup were administered to the patients in the placebo group. Both the COVID-19 and placebo syrup were identical in terms of shape and size.Each nanomedicine was provided in a separate bottle along with instructions for each. The patients in the treatment group received BCc1 twice a day (1500 mg per serving) and Hep-S once a day (1500 μg per serving) for 28 days.